{"id":782360,"date":"2023-09-07T05:33:05","date_gmt":"2023-09-07T09:33:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/"},"modified":"2023-09-07T05:33:05","modified_gmt":"2023-09-07T09:33:05","slug":"opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/","title":{"rendered":"Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MELBOURNE, Australia, Sept.  07, 2023  (GLOBE NEWSWIRE) &#8212; Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company\u2019s Chief Financial Officer will present at H.C. Wainwright\u2019s 25<sup>th<\/sup> Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11<sup>th<\/sup> \u2013 13<sup>th<\/sup>, 2023.<\/p>\n<p align=\"justify\">Mr. Morris will present on Wednesday, September 13<sup>th<\/sup> \u00a0at 12:00PM \u2013 12:30PM EST (2:00 AM September 14<sup>th<\/sup> AEDT), which can be accessed live by registering at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UldXdWAkPt6aR50YASHOaxQjg5xrhm8XihiF6hcBflW8ABYBbcVkVWotYr4YArRMEHaWxms8h4jcjo1QTmDvZQ_SKHWU_PzJzFe1RlLzRjtrd7j9-ZC0e-FNiibYu43w63IyumpSsJszuOBaVY-Zr-ML-E2t3_oitEDhEqp3SvxCuO2vvNzJJM8rSmvm3_ZFc4gZEFSm5ewBOZK-Z0yo2ts2jQKdpkH-osW1FUQtXMm8AOYQ6Awj96hj25zTl3A2hlCHOmUUlopMnM_NVTgxVwB27bMz5a7WmV0FoI9boeRjokQWnr5NOae2_9i9kdk2MdkKfkvglLUb8_9Ti3U9-Q==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/journey.ct.events\/view\/f538e04f-dd74-4f59-aa96-7164bf6856e6<\/u><\/a>. An archive of the presentation may be accessed for 90 days on the Investors page of the Opthea website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UldXdWAkPt6aR50YASHOa9qE4RCS_1-MIhX4gNPU9C3u3xcQAz9HTkEilfFELwrMN1A4btKgQJCh0EONx61ay7hMhISBIe7CsWtyZd9GgHE=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.opthea.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Opthea Limited <\/strong>\n      <\/p>\n<p align=\"justify\">Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea\u2019s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.<\/p>\n<p align=\"justify\">\n        <strong>Inherent risks of Investment in Biotechnology Companies <\/strong>\n      <\/p>\n<p align=\"justify\">There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.<\/p>\n<p align=\"justify\">\n        <strong>Authorized for release to ASX by Megan Baldwin, CEO &amp; Managing Director<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Company &amp; Media Enquiries:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>U.S.A. &amp; International:<\/strong>\n          <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>\u00a0Australia:<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Timothy E. Morris, CFO<\/td>\n<td>Rudi Michelson<\/td>\n<\/tr>\n<tr>\n<td>Opthea Limited<\/td>\n<td>Monsoon Communications<\/td>\n<\/tr>\n<tr>\n<td>Tel: +1 650-400-6874<\/td>\n<td>Tel: +61 (0) 3 9620 3333<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Media:<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Hershel Berry<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Blueprint Life Science Group<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Tel: +1 415 505 3749<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>hberry@bplifescience.com<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"3\" style=\"max-width:34%;min-width:34%\">J<strong>oin our email database to receive program updates:<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:34%;width:34%;min-width:34%\">Tel: +61 (0) 3 9826 0399<\/td>\n<td style=\"max-width:33%;width:33%;min-width:33%\">Email: info@opthea.com<\/td>\n<td style=\"max-width:33%;width:33%;min-width:33%\">Web: www.opthea.com<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODE3MCM1ODAzMDQzIzIwMjkyMjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODIzODc3MmMtMzU0My00ZmIxLThkMWMtYjFmZGNhMDE0ZTNjLTEwNDA3OTg=\/tiny\/Opthea-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company\u2019s Chief Financial Officer will present at H.C. Wainwright\u2019s 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th \u2013 13th, 2023. Mr. Morris will present on Wednesday, September 13th \u00a0at 12:00PM \u2013 12:30PM EST (2:00 AM September 14th AEDT), which can be accessed live by registering at: https:\/\/journey.ct.events\/view\/f538e04f-dd74-4f59-aa96-7164bf6856e6. An archive of the presentation may be accessed for 90 days on the Investors page of the Opthea website at https:\/\/ir.opthea.com\/. About Opthea Limited Opthea &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-782360","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company\u2019s Chief Financial Officer will present at H.C. Wainwright\u2019s 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th \u2013 13th, 2023. Mr. Morris will present on Wednesday, September 13th \u00a0at 12:00PM \u2013 12:30PM EST (2:00 AM September 14th AEDT), which can be accessed live by registering at: https:\/\/journey.ct.events\/view\/f538e04f-dd74-4f59-aa96-7164bf6856e6. An archive of the presentation may be accessed for 90 days on the Investors page of the Opthea website at https:\/\/ir.opthea.com\/. About Opthea Limited Opthea &hellip; Continue reading &quot;Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-07T09:33:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODE3MCM1ODAzMDQzIzIwMjkyMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference\",\"datePublished\":\"2023-09-07T09:33:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\"},\"wordCount\":470,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODE3MCM1ODAzMDQzIzIwMjkyMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\",\"name\":\"Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODE3MCM1ODAzMDQzIzIwMjkyMjc=\",\"datePublished\":\"2023-09-07T09:33:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODE3MCM1ODAzMDQzIzIwMjkyMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxODE3MCM1ODAzMDQzIzIwMjkyMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk","og_description":"MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) &#8212; Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company\u2019s Chief Financial Officer will present at H.C. Wainwright\u2019s 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th \u2013 13th, 2023. Mr. Morris will present on Wednesday, September 13th \u00a0at 12:00PM \u2013 12:30PM EST (2:00 AM September 14th AEDT), which can be accessed live by registering at: https:\/\/journey.ct.events\/view\/f538e04f-dd74-4f59-aa96-7164bf6856e6. An archive of the presentation may be accessed for 90 days on the Investors page of the Opthea website at https:\/\/ir.opthea.com\/. About Opthea Limited Opthea &hellip; Continue reading \"Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-07T09:33:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODE3MCM1ODAzMDQzIzIwMjkyMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference","datePublished":"2023-09-07T09:33:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/"},"wordCount":470,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODE3MCM1ODAzMDQzIzIwMjkyMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/","name":"Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODE3MCM1ODAzMDQzIzIwMjkyMjc=","datePublished":"2023-09-07T09:33:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODE3MCM1ODAzMDQzIzIwMjkyMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxODE3MCM1ODAzMDQzIzIwMjkyMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opthea-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=782360"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782360\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=782360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=782360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=782360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}